search
Back to results

Epidemiology of the Nasal Flora at the Reference Center for Cystic Fibrosis of Queen Fabiola Children's University Hospital. (FLONAMUC)

Primary Purpose

Cystic Fibrosis

Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
nasopharyngeal swab versus nasal wash
Sponsored by
Queen Fabiola Children's University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cystic Fibrosis

Eligibility Criteria

undefined - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Cystic fibrosis patients aged 0-20y followed in Cystic fibrosis at HUDERF
  • For each participant, both parents or legally acceptable representative(s) must sign an informed consent form (ICF) indicating that they understand the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study.
  • Assent is also required of children capable of understanding the study (typically participants 7 years of age and older).

Exclusion Criteria:

Any clinical situation that prohibit the taking of samples as defined in this protocol:

  • Severe respiratory distress
  • An altered state of consciousness
  • A pulmonary complication contrary to the realization of respiratory physiotherapy (pneumothorax, hemoptysis).

Sites / Locations

  • Hôpital Universitaire Des Enfants Reine Fabiola

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Nasal flora in CF patient

Arm Description

Outcomes

Primary Outcome Measures

concordance between the microbiological results obtained by nasal lavage or swab and sputum in children
To see if there is any correlation in the cultures of pathogens present in the upper and lower respiratory tracts for any combination of samples taken

Secondary Outcome Measures

Impact of upper respiratory microbial flora in the patient clinical course
To see if there is any correlation between the presence of pathogens in upper respiratory tract (URT) and the alteration of one or more clinical parameters at the time of sampling (BMI, FEV1, FVC, FEF25/75, Number of exacerbations)
Safety evaluation of the of the different methods of sampling
Type, frequency, severity and relationship between adverse events observed and sampling procedures performed.
Tolerance of the different methods of sampling
Pain / discomfort score induced by the set of sampling procedures measured by means of the "Visual Analogue Scale" (VAS) in children aged 5 or older. The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' (0) and 'pain as bad as it could be' (10). The patient is asked to mark his pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark then defines the subject's pain.
Tolerance of the different methods of sampling
Pain / discomfort score induced by the set of sampling procedures measured by means of the FLACC scale (Face, Legs, Activity, Cry, Consolability Scale) in children less than 5 years. FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. The criteria evaluated are expression of the face, position of the legs, patient activity, type of cry, consolability
Tolerance of the different methods of sampling
Percentage of Drop-out for refusal of nasal sampling

Full Information

First Posted
March 4, 2019
Last Updated
April 11, 2019
Sponsor
Queen Fabiola Children's University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03911258
Brief Title
Epidemiology of the Nasal Flora at the Reference Center for Cystic Fibrosis of Queen Fabiola Children's University Hospital.
Acronym
FLONAMUC
Official Title
Epidemiology of the Nasal Flora at the Reference Center for Cystic Fibrosis of Queen Fabiola Children's University Hospital.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
February 6, 2019 (Actual)
Primary Completion Date
April 30, 2020 (Anticipated)
Study Completion Date
April 30, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Queen Fabiola Children's University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cystic fibrosis (CF) is the most common autosomal recessive inherited genetic disorder in North America, Australia and Europe. CF is due to cystic fibrosis transmembrane conductance regulator gene mutation (CFTR) coding for a chloride channel located at the apical membrane of epithelial cells. The most common mutation is the deletion of the amino acid phenylalanine at the codon 508 (ΔF508) affecting 70% of the patients. The CFTR channel participates in the regulation of the volume and composition of exocrine secretions. At the level of the lungs, this results in a thickening of the mucus with a dysfunction of the mucociliary clearance promoting colonization of pathogenic microorganisms. Patients with cystic fibrosis therefore have a natural susceptibility to develop acute and then chronic respiratory infections, gradually leading to irreversible respiratory tract lesions called bronchiectasis. Different germs such as Haemophilus influenzae and Staphylococcus aureus colonize the airways early in life. The progression of the disease causes furthermore a colonization by opportunistic germs such as Pseudomonas aeruginosa and Burkholderia cepacia, which are associated with higher mortality. Pulmonary exacerbation is a common complication of CF requiring administration of antibiotics. The choice of these antibiotics depends on the germs that the patient carries in his respiratory tract. The type of sampling and the conditions under which they are taken are therefore very important. Sputum and oropharyngeal smear are used in adolescents and children respectively to collect respiratory secretions in clinical routine. The recent literature describes induced sputum, obtained after a physiotherapy session and a hypertonic serum aerosol, as superior to the oropharyngeal smear alone and equivalent to bronchoalveolar lavage for the evaluation of the microbiological profile of patients who cannot expectorate. However, this technique takes time and requires the presence of a physiotherapist. Bronchoalveolar lavage is reserved for complex cases that do not respond to standard treatments. Finally, the nasal flora appears to be involved in the colonization of the lower respiratory tract. Sinuses are described as reservoirs of germs that can induce a recolonization of the lungs despite eradication of the germ (for example after a pulmonary transplantation) . To our knowledge, no study has investigated the involvement of nasal flora in the clinical course of children with CF.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nasal flora in CF patient
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
nasopharyngeal swab versus nasal wash
Intervention Description
The type of procedure will be determine according to patient collaboration
Primary Outcome Measure Information:
Title
concordance between the microbiological results obtained by nasal lavage or swab and sputum in children
Description
To see if there is any correlation in the cultures of pathogens present in the upper and lower respiratory tracts for any combination of samples taken
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Impact of upper respiratory microbial flora in the patient clinical course
Description
To see if there is any correlation between the presence of pathogens in upper respiratory tract (URT) and the alteration of one or more clinical parameters at the time of sampling (BMI, FEV1, FVC, FEF25/75, Number of exacerbations)
Time Frame
Day 60
Title
Safety evaluation of the of the different methods of sampling
Description
Type, frequency, severity and relationship between adverse events observed and sampling procedures performed.
Time Frame
Day 1
Title
Tolerance of the different methods of sampling
Description
Pain / discomfort score induced by the set of sampling procedures measured by means of the "Visual Analogue Scale" (VAS) in children aged 5 or older. The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' (0) and 'pain as bad as it could be' (10). The patient is asked to mark his pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark then defines the subject's pain.
Time Frame
Day 1
Title
Tolerance of the different methods of sampling
Description
Pain / discomfort score induced by the set of sampling procedures measured by means of the FLACC scale (Face, Legs, Activity, Cry, Consolability Scale) in children less than 5 years. FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. The criteria evaluated are expression of the face, position of the legs, patient activity, type of cry, consolability
Time Frame
Day 1
Title
Tolerance of the different methods of sampling
Description
Percentage of Drop-out for refusal of nasal sampling
Time Frame
Day 60

10. Eligibility

Sex
All
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cystic fibrosis patients aged 0-20y followed in Cystic fibrosis at HUDERF For each participant, both parents or legally acceptable representative(s) must sign an informed consent form (ICF) indicating that they understand the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is also required of children capable of understanding the study (typically participants 7 years of age and older). Exclusion Criteria: Any clinical situation that prohibit the taking of samples as defined in this protocol: Severe respiratory distress An altered state of consciousness A pulmonary complication contrary to the realization of respiratory physiotherapy (pneumothorax, hemoptysis).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Christophe Beghin, MD
Organizational Affiliation
Queen Fabiola Children's University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Universitaire Des Enfants Reine Fabiola
City
Brussels
ZIP/Postal Code
1020
Country
Belgium

12. IPD Sharing Statement

Learn more about this trial

Epidemiology of the Nasal Flora at the Reference Center for Cystic Fibrosis of Queen Fabiola Children's University Hospital.

We'll reach out to this number within 24 hrs